What Ultraproct (VASOPROTECTIVES) Treats: Main Uses and Benefits

Ultraproct is applied in clinical settings that involve acute or unstable symptom patterns, and is used for managing groups of symptoms that may become intense or disruptive. The preparation is relevant for conditions characterized by periods of heightened symptoms, including internal and external haemorrhoids (piles), proctitis, and superficial anal fissures. This medication is commonly used to help address symptoms related to physical discomfort, such as soreness, throbbing pain, and anal spasm, and may assist with maintaining a sense of stability when symptoms are more noticeable.

It is relevant in contexts involving heightened systemic burden and symptoms related to inflammatory or irritative states, and is relevant for easing these symptoms that interfere with daily comfort, particularly severe pruritus ani (anal itching). Applied in scenarios where supportive symptom management is appropriate, the medication provides short-term symptomatic assistance that helps ease the overall symptom burden, supporting the patient during difficult episodes.

Quick Fact: Support for Acute Symptomatic Periods

Property	Description
Primary Focus	Symptom clusters that are intense or disruptive
Main Benefit	Supports the patient during difficult episodes and helps ease distress
Usage Context	Applied during phases when symptoms become more noticeable
Associated Symptoms	Pain, swelling, irritation, and pruritus ani

Regulatory References

1. New Zealand Medsafe Data Sheet

Who Can and Cannot Use Ultraproct (VASOPROTECTIVES)?

Official regulatory documentation defines specific populations and conditions under which the use of Ultraproct is prohibited or restricted.

---

Contraindications and Non-Eligible Conditions

Ultraproct is strictly contraindicated and must not be used by individuals with a documented hypersensitivity to the active ingredients (Fluocortolone or Cinchocaine) or any other components of the preparation. Use is also prohibited in the presence of infectious diseases at the application site, including tuberculous or syphilitic processes, and viral diseases such as chickenpox, shingles, or Herpes simplex.

Age-Related and Conditional Restrictions

Population	Regulatory Status
Infants	Not for use
Children under 12	Not recommended (conditional use requires doctor's direction)
Pregnancy (1st Trimester)	Generally should not be applied

For primary bacterial or fungal infections in the treatment area, use is conditional: the medicine must only be applied if concurrent, appropriate anti-infective therapy is being administered. Use during the second and third trimesters of pregnancy and during lactation is conditional, requiring a doctor's careful review of benefits versus risks, and prolonged use must be avoided.

The official interaction profile for Ultraproct is strictly defined by a pharmacokinetic interaction related to the metabolism of its corticosteroid component, Fluocortolone. This interaction is documented in regulatory sources such as the Summary of Product Characteristics (SmPC).

Interaction Scope and Restrictions

The primary category of medicinal products documented to interact are CYP3A inhibitors. These agents are expected to inhibit the enzyme pathway responsible for metabolizing the Fluocortolone component, which can potentially lead to an increased systemic exposure of the corticosteroid.

Specific interacting medicines cited in official documents include cobicistat-containing products. Due to the expected increase in systemic exposure, the interaction is formally classified as carrying an increased risk of systemic corticosteroid side-effects.

Regulatory documents state that co-treatment with CYP3A inhibitors should be avoided unless the clinical necessity for the combination is judged to outweigh the documented systemic risk. In cases where the combination is used, regulatory guidance directs that patients should be monitored for signs of systemic corticosteroid effects.

Interaction Context Constraints

The Ultraproct interaction profile is otherwise limited. Official regulatory documentation states the absence of documented interactions with food, alcohol, herbal products, or other medicinal agents outside the CYP3A pathway. Furthermore, no mandatory timing-based administration rules or population-specific interaction considerations are stated in the official labels.

Ultraproct is a combination product whose pharmacodynamic action is mediated by two active components: fluocortolone and cinchocaine.

Fluocortolone is a synthetic glucocorticoid that operates as an agonist at the intracellular glucocorticoid receptor ( GR), primarily within endothelial cells, leukocytes, and mast cells. Upon binding, the activated drug-receptor complex translocates to the nucleus and modulates gene transcription by binding to glucocorticoid response elements ( GREs). This genomic action results in the transcription and synthesis of anti-inflammatory proteins, such as annexin A1 (also known as lipocortin-1). Annexin A1 inhibits the activity of the enzyme phospholipase A2 ( PLA2), thereby blocking the release of arachidonic acid from cell membrane phospholipids. This interruption in the arachidonic acid cascade prevents the synthesis of downstream vasoactive and inflammatory mediators, specifically prostaglandins and leukotrienes. The physiological consequence is a direct modulation of vascular permeability and a reduction in cellular extravasation at the targeted tissue.

Cinchocaine functions as an inhibitor of voltage-gated sodium channels ( Na V) on the neuronal membrane. It binds to the intracellular portion of the channel, stabilizing it in an inactivated state. This blockade prevents the rapid influx of sodium ions necessary for cell depolarization, thereby inhibiting the initiation and propagation of the neuronal action potential. This systemic effect is localized nerve impulse conduction blockade, resulting in the interruption of afferent signaling.

Ultraproct, which contains the corticosteroid fluocortolone and the local anesthetic cinchocaine, is used to manage symptoms of hemorrhoids, anal fissures, and proctitis. This medication is intended for short-term use, generally not exceeding four weeks, unless specifically advised by a healthcare provider.

---

General Application Guidance

Always use Ultraproct exactly as prescribed by your doctor. The best time to apply the medication is generally after a bowel movement. Before application, gently but thoroughly wash and dry the anal region, and wash your hands both before and after use to prevent infection and irritation.

---

Dosage and Administration

Formulation	Initial Application (First Day)	Follow-up Application	Instructions and Notes
Ointment	Up to four times daily for rapid relief	Typically twice daily	Apply a small amount (pea-sized) to the affected area. For internal application, the provided nozzle should be used and cleaned thoroughly after each use.
Suppositories	One suppository two to three times daily for severe symptoms	Typically one suppository daily	Insert one suppository high into the rectum. Suppositories should be stored in the refrigerator (2°C to 8°C) but can be briefly placed in cold water before unwrapping if they have softened.

To prevent recurrence, it is often recommended to continue treatment with a reduced frequency (e.g., ointment once a day or one suppository every other day) for about one week after symptoms have fully disappeared. Do not use Ultraproct for more than four weeks; prolonged use of corticosteroids may lead to skin thinning and other local side effects.

Research Exploring Symptoms in Haemorrhoids (Piles)

Research exploring how symptoms change over time has primarily focused on adults experiencing acute symptomatic haemorrhoids or flare-ups of chronic hemorrhoidal disease. Studies conducted during periods of increased symptom activity have primarily been prospective observational cohort studies, tracking groups of patients in real-world settings. Researchers examined measurements of patient-reported severity for key symptoms, including pain, swelling, itching, and bleeding, over a short-term period, typically around 14 days. Findings describe patterns observed in the studies related to the assessment of these acute symptoms. While these findings help contextualize patient reported experience, the certainty remains moderate because the evidence is largely derived from observational research.

---

Research Context for Superficial Anal Fissures and Proctitis

Research has also explored Ultraproct in the context of symptoms associated with superficial anal fissures and proctitis, conditions characterized by fluctuating or episodic manifestations. Foundational clinical evaluations and trials were conducted, supporting the inclusion of these as registered uses. For fissures, research examined assessment of pain and physical signs of healing. For proctitis, studies monitored changes related to inflammation, rectal discharge, and discomfort. Reported data describe patterns related to symptom evolution in the studied populations. However, the evidence quality varies across studies, and certainty remains low for these indications.

---

Long-Term Data and Key Limitations

Evidence for the effects of Ultraproct beyond the immediate treatment period is not fully established. Studies exploring short-term symptom changes provide limited insight into how durable the observed effects may be once treatment has stopped. The research focus has been predominantly on periods of heightened symptom activity, and comparative evidence is lacking regarding long-term maintenance or recurrence prevention. Furthermore, data are limited regarding pediatric or specific comorbidity-defined populations, meaning the evidence contributes little to understanding long-term effects or recurrence patterns in these groups.

Key Studies & References

1. Ultraproct suppositories data sheet (New Zealand Medsafe)
2. Anatomical Therapeutic Chemical (ATC) Classification System - C05AA Corticosteroids combined with local anesthetics

Common questions about Ultraproct (VASOPROTECTIVES) (FAQ)

---

Q: Is Ultraproct an over-the-counter medicine or prescription only?

Official regulatory documents classify Ultraproct as a prescription-only medicine (POM). This means that a doctor’s medical prescription is required to obtain this product.

Q: How quickly can a person expect to feel the effects of Ultraproct?

The product's composition is designed to offer rapid symptomatic relief. Official information notes that the cinchocaine component, a local anaesthetic, is included to provide immediate relief from pain and discomfort.

Q: Are there any common reasons a doctor might choose Ultraproct over other treatments?

Ultraproct is a fixed-dose combination product, meaning it contains two active ingredients: a corticosteroid to address inflammation and swelling, and a local anaesthetic for immediate pain relief. This dual action makes it suitable for the symptomatic management of acute, painful anal conditions, as described in official product information.

Q: Does Ultraproct interact with common pain relievers like paracetamol or ibuprofen?

Official regulatory documents state that specific interaction studies involving common pain relievers like paracetamol or ibuprofen have not been performed. The documented interaction profile primarily focuses on medicines that may affect the metabolism of the corticosteroid component, known as CYP3A inhibitors.

Q: Are there any known interactions between Ultraproct and common blood pressure medicines?

Official regulatory documents state that specific interaction studies involving common blood pressure medicines have not been performed. The medicine’s documented interaction profile focuses mainly on medicines known as CYP3A inhibitors.

Q: How does Ultraproct differ from creams that only contain a single active ingredient?

Ultraproct is defined as a fixed-dose combination product because it contains two active components. These are the corticosteroid fluocortolone, which suppresses inflammation and swelling, and the local anaesthetic cinchocaine, which provides pain relief.

Q: What happens if Ultraproct is exposed to sunlight or extreme heat?

The product's stability depends on proper storage conditions. The ointment is required to be stored below 25 C (77 F), and suppositories are required to be stored in a refrigerator (between 2 C and 8 C). Exposure to extreme temperatures, such as direct sunlight or excessive heat, is stated to be necessary to avoid to maintain the quality of the medication.

Q: What documents describe the ingredients Ultraproct is made of?

The full list of ingredients, including the active components and excipients (inactive substances), is documented in the official regulatory documents, such as the Summary of Product Characteristics (SmPC). These documents also provide warnings about specific excipients, such as those in the ointment that may affect the effectiveness of latex products like condoms.

Q: Does official guidance state Ultraproct should be stopped gradually or can it be stopped immediately?

Official guidance describes a protocol for a reduced frequency of application for about one week after symptoms have fully disappeared. This is suggested to help prevent recurrence.

Q: Does Ultraproct contain ingredients to protect the veins or blood vessels?

Ultraproct is classified as a vasoprotective, and its fluocortolone component is a corticosteroid with vasoconstrictive properties. This means it helps to narrow the blood vessels in the area, which, in turn, helps to suppress localised inflammation and swelling.

Q: Is it normal to feel a slight stinging or burning sensation when first applying Ultraproct?

Although local skin atrophy and allergic reactions are the main adverse reactions listed in official documents, reports indicate that a local burning sensation may occasionally occur in the anal region.

Q: If a dose of Ultraproct is missed, what is the generally described action?

Official patient information advises against using extra medication to make up for the missed one. The guidance provided suggests applying the next prescribed dose at the regularly scheduled time to continue with the treatment schedule.

Q: Does using Ultraproct impact the ability to drive or operate machinery?

The official product label explicitly states that Ultraproct is not known to affect or impair a person’s ability to drive vehicles or operate heavy machinery.

Q: What information is provided about potential overdose symptoms of Ultraproct?

Regulatory reports indicate that no acute risk of intoxication is expected from a single, inadvertent topical overdose. However, if the preparation is accidentally swallowed, systemic effects, primarily related to the cinchocaine component (a local anaesthetic), could potentially affect the cardiovascular system.

Q: Can Ultraproct be used by people with a history of glaucoma?

Official product warnings state that visual disturbances, such as blurred vision, may occur and referral to a specialist is advised for evaluation. The warning mentions that such evaluations may be necessary to check for possible underlying causes, which may include conditions like glaucoma or cataract.

Q: Are there different strengths of Ultraproct available globally?

The Ultraproct ointment and suppositories are fixed-dose combination products. The components are available in specific, consistent strengths, which are documented in regulatory product databases across different countries (e.g., 5mg/g of Cinchocaine in the ointment).

How to Store and Dispose of Ultraproct (VASOPROTECTIVES)

Official regulatory documents define specific storage and handling requirements for Ultraproct, which differ by formulation to maintain stability.

---

Mandatory Storage Conditions

Formulation	Required Storage Condition (Official Labeling)
Suppositories	Must be stored in a refrigerator (2 C to 8 C / 36 F to 46 F).
Ointment	Must be stored at a temperature below mathbf25 C (mathbf77 F).

---

Handling, Stability, and Disposal

The suppositories must not freeze. If the suppositories soften, their consistency can be restored by placing them in cold water before removal from the packaging. The medication must not be used after the expiry date.

Both formulations must be kept out of the sight and reach of children.

Unused or expired product must be disposed of in accordance with local regulations. Patients should consult a pharmacist for guidance on proper pharmaceutical waste disposal.